Danish allergy immunotherapy specialists ALK-Abelló (ALKB: DC) today announced it has received FDA approval for its house dust mite sublingual allergy immunotherapy (SLIT) tablet.
The US Food and Drug Administration has approved the Biologics License Application (BLA) for the treatment, indicated as an immunotherapy for house dust mite (HDM)-induced allergic rhinitis, with or without conjunctivitis.
The BLA had been submitted by MSD, the Merck & Co (NYSE: MRK) subsidiary, as part of a licensing agreement which subsequently came to an end.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze